Cancer Prevention and Control CIRB Meeting Agenda

July 23, 2020

I. Amendment Prior to Activation

NRG-CC005, FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps) (Protocol Version Date 06/16/20)

II. Continuing Review

A171601, A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer (Protocol Version Date 05/29/20)

III. Continuing Review

A221805, Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Protocol Version Date 02/04/20)

IV. Continuing Review

MDA2017-09-03, Pilot Study of Denosumab in BRCA1/2 Mutation Carriers scheduled for Risk-reducing Salpingooophorectomy (Protocol Version Date 05/15/20)

V. Continuing Review

S1600, A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (Protocol Version Date 08/30/19)

VI. Continuing Review

UWI2015-05-01, Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect (Protocol Version Date 05/27/20)
VII. New Study Review

NWU20-01-03, Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): RELIEF-NAFLD (Protocol Version Date 07/15/20)

VIII. Amendment

URCC-18110CD, Implementing Palliative Care: Learning Collaborative vs. Technical Assistance (Protocol Version Date 05/27/20)

IX. Amendment

WF-97415, Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT) (Protocol Version Date 06/26/20)